search
Back to results

Analgesic Effect of Liposomal Bupivacaine

Primary Purpose

Acute Pain

Status
Active
Phase
Phase 4
Locations
Hong Kong
Study Type
Interventional
Intervention
Bupivacaine Injection [Marcaine]
Bupivacaine Liposome 13.3 MG/ML [Exparel]
Sponsored by
The University of Hong Kong
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Acute Pain

Eligibility Criteria

18 Years - 90 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • American Society of Anesthesiologist (ASA) status I-III
  • Age 18-90 years old
  • Scheduled for distal radial fracture fixation (Open reduction and internal fixation with volar approaching locking plate)

Exclusion Criteria:

  • Revision surgery
  • Previous fractures or surgery in the affected distal radius
  • Surgery involving more than the affected arm
  • Higher energy and high-grade fracture cases - road traffic accident, fall from height, open fractures, combined distal radius and distal ulna fractures, fractures requiring external fixation, fractures with severe articular comminution or severe metaphyseal extension, comminuted fractures requiring more than a single volar approach incision and a single volar locking plate implant
  • Cases with painful conditions affecting the upper limb prior to surgery such as cervical spine, shoulder, elbow, other hand and wrist problems
  • Cases with baseline (pre-injury) qDASH score worse than 10 out of 100
  • Respiratory compromise (requires long term oxygen)
  • History of seizures
  • Pre-existing neurological disorder/deficit
  • Chronic opioid user
  • Presence of chronic pain condition (pain duration over 3 months)
  • Alcohol or substance abuse
  • Active smoker
  • Psychiatric illness
  • Impaired mental state
  • Local infection
  • Allergy to analgesic drugs: local anaesthetic drugs, paracetamol, non-steroidal anti-inflammatory drugs (NSAIDs), opioids
  • Impaired renal function (defined as effective glomerular filtration rate less than 30ml/min/1.73m2
  • Impaired liver function (defined as plasma bilirubin over 34micromol/L; international normalized ratio [INR] 》/=1.7, alanine aminotransferase [ALT] over 100U/L, aspartate aminotransferase [AST] over 100U/L)
  • Coagulopathy (platelet count 《100,000/ml and/or INR 》/=1.5) or the use of anticoagulants (not including aspirin) that precludes the use of supraclavicular BPB
  • Pregnancy
  • Patient refusal for regional nerve blocks
  • Patient refusal to join the clinical trial
  • Patient unable/unwilling to attend post-op rehabilitation programme
  • Injury on duty

Sites / Locations

  • The University of Hong Kong

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

To receive supraclavicular BPB using standard ropivacaine only.

To receive supraclavicular BPB using liposomal bupivacaine together with ropivacaine.

Arm Description

20ml of plain bupivacaine will be injected using 2 syringes, so 10ml of 0.5% plain bupivacaine will be injected, and immediately followed by another 10ml of 0.5% plain bupivacaine.

10ml of 0.5% plain bupivacaine will be injected, and immediately followed by 10ml of 1.33% liposomal bupivacaine.

Outcomes

Primary Outcome Measures

postoperative AUC pain score at rest
Pain severity would be rated at rest after surgery using numerical rating scale with 0 to 10 where 0=no pain and 10=the worst possible pain

Secondary Outcome Measures

Full Information

First Posted
November 1, 2021
Last Updated
July 21, 2023
Sponsor
The University of Hong Kong
search

1. Study Identification

Unique Protocol Identification Number
NCT05118399
Brief Title
Analgesic Effect of Liposomal Bupivacaine
Official Title
Addition of Liposomal Bupivacaine to Standard Bupivacaine Versus Standard Bupivacaine Alone in the Supraclavicular Brachial Plexus Block: a Randomized Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
November 15, 2021 (Actual)
Primary Completion Date
March 13, 2023 (Actual)
Study Completion Date
December 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
The University of Hong Kong

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Brachial plexus blocks (BPB) are commonly used to provide regional anaesthesia for patients undergoing distal radial fracture surgery. Distal radial (DR) fracture surgery is a commonly performed orthopaedic surgery, and is usually associated with moderate postoperative pain. Poor postoperative pain control can impair rehabilitation, delay recovery and negatively impact outcomes after surgery. Liposomal bupivacaine (EXPAREL) is a multivesicular formulation of bupivacaine that allows rapid absorption and prolonged release of bupivacaine. Liposomal bupivacaine can provide longer analgesia for up to 72 hours, and may therefore achieve greater analgesic efficacy compared to non-liposomal long-acting local anaesthetics. A number of clinical trials have studied the effect liposomal bupivacaine given as local infiltration. However, there is little evidence on liposomal bupivacaine for regional nerve blocks, and the use of liposomal bupivacaine for supraclavicular brachial plexus block - which is used for regional anaesthesia for distal radial fracture surgery - have not been studied before. This project is a randomized controlled trial to determine whether adding liposomal bupivacaine to long-acting local anaesthetics for supraclavicular BPB will improve and prolong postoperative analgesia in patients undergoing distal radial fracture surgery. Longer term secondary outcomes would be accessed including upper limb functional scores, chronic pain, and health related quality of life.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acute Pain

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
80 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
To receive supraclavicular BPB using standard ropivacaine only.
Arm Type
Active Comparator
Arm Description
20ml of plain bupivacaine will be injected using 2 syringes, so 10ml of 0.5% plain bupivacaine will be injected, and immediately followed by another 10ml of 0.5% plain bupivacaine.
Arm Title
To receive supraclavicular BPB using liposomal bupivacaine together with ropivacaine.
Arm Type
Experimental
Arm Description
10ml of 0.5% plain bupivacaine will be injected, and immediately followed by 10ml of 1.33% liposomal bupivacaine.
Intervention Type
Drug
Intervention Name(s)
Bupivacaine Injection [Marcaine]
Intervention Description
Bupivacaine injection [Marcaine] is the standard treatment used in our hospital.
Intervention Type
Drug
Intervention Name(s)
Bupivacaine Liposome 13.3 MG/ML [Exparel]
Intervention Description
Bupivacaine liposome is a multivesicular formulation of bupivacaine that allows rapid absorption and prolonged release of bupivacaine.
Primary Outcome Measure Information:
Title
postoperative AUC pain score at rest
Description
Pain severity would be rated at rest after surgery using numerical rating scale with 0 to 10 where 0=no pain and 10=the worst possible pain
Time Frame
First 48 hours after surgery

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
90 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: American Society of Anesthesiologist (ASA) status I-III Age 18-90 years old Scheduled for distal radial fracture fixation (Open reduction and internal fixation with volar approaching locking plate) Patients with informed consent to participate in the study Exclusion Criteria: Ulnar shaft/ neck physis fracture Revision surgery Previous fractures or surgery in the affected distal radius Surgery involving more than the affected arm Higher energy and high-grade fracture cases - road traffic accident, fall from height, open fractures, combined distal radius and distal ulna fractures, fractures requiring external fixation, fractures with severe articular comminution or severe metaphyseal extension, comminuted fractures requiring more than a single volar approach incision and a single volar locking plate implant Cases with painful conditions affecting the upper limb prior to surgery such as cervical spine, shoulder, elbow, other hand and wrist problems Cases with baseline (pre-injury) QuickDASH score worse than 10 out of 100 Respiratory compromise (requires long term oxygen) History of seizures Pre-existing neurological disorder/deficit Chronic opioid user (use for 3 months or more) Presence of chronic pain condition (pain duration over 3 months) Alcohol or substance abuse Psychiatric illness Impaired mental state Local infection Allergy to analgesic drugs: local anaesthetic drugs, paracetamol, non-steroidal anti-inflammatory drugs (NSAIDs), opioids Impaired renal function (defined as effective glomerular filtration rate less than 30ml/min/1.73m2 Impaired liver function (defined as plasma bilirubin over 34micromol/L; international normalized ratio [INR] 》/=1.7, alanine aminotransferase [ALT] over 100U/L, aspartate aminotransferase [AST] over 100U/L) Coagulopathy (platelet count 《100,000/ml and/or INR 》/=1.5) or the use of anticoagulants (not including aspirin) that precludes the use of supraclavicular BPB Pregnancy Patient refusal for regional nerve blocks Patient refusal to join the clinical trial Patient unable/unwilling to attend post-op rehabilitation programme Injury on duty
Facility Information:
Facility Name
The University of Hong Kong
City
Hong Kong
Country
Hong Kong

12. IPD Sharing Statement

Learn more about this trial

Analgesic Effect of Liposomal Bupivacaine

We'll reach out to this number within 24 hrs